Magnetic susceptibility contrast variations in multiple sclerosis lesions
Xu Li(Kennedy Krieger Institute), Peter C.M. van Zijl(Kennedy Krieger Institute), Jiwon Oh(St. Michael's Hospital), Daniel M. Harrison(University of Maryland, Baltimore), Hongjun Liu(Shandong Provincial Hospital), Peter A. Calabresi(Johns Hopkins University), Craig Jones(Johns Hopkins University)
Cited by 93
Related Papers
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
|The Lancet|2011|743
2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis
|The Lancet Neurology|2021|646
Multiple sclerosis progression: time for a new mechanism-driven framework
|The Lancet Neurology|2022|624
Multiple sclerosis: clinical aspects
|Current Opinion in Neurology|2018|609